

Zyflamend is a formulation containing ten different herbs (1). It is promoted as having anti-inflammatory and antiaging properties. Supporters claim the beneficial effects of Zyflamend are due to the constituents, many of which reduce inflammation by decreasing cyclooxygenase-2 (COX-2) activity. In vitro studies showed that Zyflamend inhibits COX-1 and COX-2 enzymes, induces apoptosis (4), and inhibits proliferation (8) of human prostate cancer cells.
Results from a small phase I trial of Zyflamend indicate a reduction in prostate specific antigen (PSA) levels in men with prostatic intraepithelial neoplasia (PIN) (7). More studies are warranted.
Holy basil, turmeric, ginger, green tea, rosemary, hu zhang, Chinese gold thread and Scutellaria inhibit cyclooxygenase-2 activity and thereby reduce inflammation. In vitro, Zyflamend reduced the proliferation of prostate cancer cells by inhibiting COX-2 activity and by inducing apoptosis (2). It also down-regulated NF-kappa B activiation (6) and inhibited leukotriene B4 formation in an animal carcinogenesis model (5).
The FDA issued a letter to an Internet distributor for exaggerated claims made for Zyflamend (3). Individuals using Zyflamend should be cautious of such claims.
Women who are pregnant or nursing should consult their physicians before using Zyflamend.
Hypersensitivity to any of the constituents.
The herbal constituents of Zyflamend can potentially interact with prescription drugs.
Bottom Line: Zyflamend has not been shown to treat cancer.
Zyflamend is a herbal supplement consisting of Holy basil, turmeric, ginger, green tea, rosemary, hu zhang, Chinese goldthread, barberry, oregano, and scullcap. Promoters of Zyflamend claim that it has anti-inflammatory and antiaging effects. It has been shown in one laboratory study to reduce inflammation and cause cell death. Results from a small study indicate it may help lower prostate specific antigen (PSA), a marker of prostate cancer. More research is needed.
One laboratory study showed that Zyflamend reduced the number of prostate cancer cells by inactivating the COX-2 enzyme activity and by inducing cell death.
The FDA issued a letter to an Internet distributor for exaggerated claims made for Zyflamend. Individuals taking Zyflamend should inform their physicians.
Women who are pregnant or nursing should consult their physicians before using Zyflamend.
If you have hypersensitivity to any of the constituents.